The HER2 + molecular subtype is the most common subtype among IBC patients and is more prevalent than the corresponding subtype in nIBC (nIBC), yet the efficacy of treatment for IBC remains considerably lower [6]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.